NCT00061425已完成1 期
Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
研究概览
简要总结
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Safety Study of NHL With 90Y-hLL2 IgGB-cell NHLNon-Hodgkins LymphomaNHLNCT00421395Gilead Sciences59
终止
1 期
Study of 90Y-hLL2 to Treat Non-Hodgkin's LymphomaNon-Hodgkins LymphomaNCT00054834Gilead Sciences27
已完成
1 期
Safety Study of 90Y-hMN14 to Treat Colorectal CancerRectal CancerColorectal CarcinomaColorectal CancerColon CancerColorectal NeoplasmsColorectal TumorNCT00040599Gilead Sciences72
已完成
1 期
Safety Study of 90Y-hMN14 to Treat Pancreatic CancerPancreatic NeoplasmsNCT00041639Gilead Sciences75
已完成
1 期
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin LymphomaNon-Hodgkin LymphomaNCT00302757University Hospital Tuebingen60